• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
J Neurosci. Author manuscript; available in PMC Feb 17, 2011.
Published in final edited form as:
PMCID: PMC3040577
NIHMSID: NIHMS103431

Evolutionary conservation of vertebrate blood-brain barrier chemoprotective mechanisms in Drosophila

Abstract

Pharmacologic remedy of many brain diseases is difficult because of the powerful drug exclusion properties of the blood-brain barrier (BBB). Chemical isolation of the vertebrate brain is achieved through the highly integrated, anatomically compact and functionally overlapping chemical isolation processes of the BBB. These include functions that need to be coordinated between tight diffusion junctions and unidirectionally-acting xenobiotic transporters. Understanding of many of these processes has been hampered, as they are not well mimicked by ex vivo models of the BBB and have been experimentally difficult and expensive to disentangle in intact rodent models. Here we show that the Drosophila melanogaster (Dm) humoral/CNS barrier conserves the xenobiotic exclusion properties found in the vertebrate vascular endothelium. We characterize a fly ABC transporter, Mdr65, that functions similar to mammalian xenobiotic BBB transporters and show that varying its levels solely in the Dm BBB changes the inherent sensitivity of the barrier to cytotoxic pharmaceuticals. Furthermore we demonstrate orthologous function between Mdr65 and vertebrate ABC transporters by rescuing chemical protection of the Dm brain with human MDR1/Pgp. These data indicate that the ancient origins of CNS chemoprotection extend to both conserved molecular means and functionally analogous anatomic spaces that together promote CNS selective drug partition. Thus, Dm presents an experimentally tractable system for analyzing physiological properties of the BBB in an intact organism.

Keywords: Blood-brain barrier, drosophila, neuroprotection, pharmacokinetics, ABC transport, genetic screen

Introduction

In vertebrates, a physically separate blood-brain barrier, primarily engineered into the single-cell layer vascular endothelium (VE), provides an obstacle to chemical attack. At this interface, strong selective pressures have produced the integration of at least two very different cell biologic mechanisms to prevent free movement of small molecules between the humoral and CNS interstitial compartments. (Abbott, 2005; Daneman and Barres, 2005; Neuwelt et al., 2008; Zlokovic, 2008). BBB VE cells impede the traffic of drugs by virtue of specialized lateral junction components, including tight junctions, and asymmetrically arrayed ATP binding cassette (ABC) transporters. Tight junctions prevent paracellular diffusion of charged molecules and asymmetrically arrayed transporters actively expel lipophilic molecules back into the humoral space (Loscher and Potschka, 2005b). Together, these complimentary systems prevent the majority of xenobiotics from acting on vertebrate nervous tissue (Pardridge, 2005a, b). Although in vivo and in vitro BBB models have confirmed the importance of these two components (Schinkel et al., 1997; Nitta et al., 2003), substantial limitations hinder progress (Garberg et al., 2005). A powerful BBB model system should combine molecular genetic, genomic, chemical biology and integrative physiology tools to probe CNS-specific chemoprotective physiology. For this we turned to Drosophila melanogaster and asked what aspects of BBB physiology can be modeled in an invertebrate.

Insects also possess protective neural barriers, but they differ anatomically from vertebrates (Figure 1). Drosophila melanogaster (Dm) has an open circulatory system that is separated from the CNS by a thin layer of glially-derived epithelial cells (Treherne JE, 1972; Carlson et al., 2000; Stork et al., 2008), making the Dm humoral/CNS interface topologically much simpler than the vertebrate BBB. However on a cellular level, the vertebrate and insect BBBs share many common features. In particular, one specific cell layer of the Dm BBB, the sub-perineural glia (SPG), possesses elaborate laterally-localized homotypic junctional complexes, or pleated septate junctions, that create a tight barrier to paracellular diffusion (Edwards et al., 1993; Tepass and Hartenstein, 1994). The Dm proteins that make up the pleated septate junctions are nearly identical to the vertebrate proteins that compose the tight junctions (Wu and Beitel, 2004; Banerjee et al., 2006). Furthermore, disruption of the pleated septate junctions leads to defects in Dm BBB function (Schwabe et al., 2005; Stork et al., 2008), however the dual nature of localized xenobiotic protection mechanisms had not been established in insects.

Figure 1
Visualization of drug transport in vivo through the Dm retina

Here, we demonstrate molecular and architectural similarities between fly and vertebrate BBBs by showing that Mdr65, a homolog of the major ABC transporter found at the human BBB, MDR1/Pgp, is required for normal chemical protection of the Dm brain. We show that the fruit fly (Dm) is uniquely suited for live assays of BBB function, making it useful for genetic screens and real time assessment of chemical partition phenomena. We further show that Mdr65 is specifically localized at the humoral barrier of the Dm CNS, indicating that the SPG, like the vertebrate VE, possesses both tight diffusion barriers and active efflux transporters. Our findings show strong evolutionary conservation of localized chemoprotective mechanisms and establish Dm as a tractable system for studying the regulatory mechanisms and integrated neuro-protective physiologies of the BBB in vivo.

Materials and Methods

Drosophila Culture and Genetics

Animals are grown on standard cornmeal molasses agar media at 25°C and 70% humidity in uncrowded bottles and collected two days prior to eclosion.

Intrahemolymph Drug Dosing

Dosing methods are similar to those previously described in Bainton et al, 2005. In short, intrahumoral fluor and drug doses are delivered by placing a microinjection needle between the posterior abdominal wall body segments of CO2 anesthetized animals. Positive pressure is applied to the needle under direct visualization over 1–2 seconds to deliver an average volume of 100 nL dye per injection s.d. +/− 25 (range 70–130 nl, data not shown). Animals are allowed to recover from injection in food vials at 25°C. In Fig.1, drugs and dyes were dosed using the following concentrations: Texas Red-Dextran (TRD) 25 mg/mL, FITC salt 1mg/ml, Rhodamine 123 (Rho123) 1.25 mg/mL, Cyclosporin A 250 uM and/or GF120918, 50 uM.

Retinal Images Acquisition

All retinal images were taken of animals under CO2 anesthesia using methods described in Bainton et al, 2005.

In situ brain staining

Animals to be stained with C219 antibody are injected with 200 uM cyclosporine A in H2O (Sigma, C 1832, St. Louis, MO) and 25 mg/ml 3 kDa Cascade blue dextran (Invitrogen, D-7132, Carlsbad, CA) and allowed to recover overnight. Cyclosporine A holds ABC B1 in an open conformation and improves C219 antibody staining in situ (Demeule et al., 1995; van Den Elsen et al., 1999). Flies are anesthetized with CO2, decapitated, and the proboscis removed. Whole heads are placed in fixative (3.7% paraformaldehyde in 1X PBS) for 15 minutes at room temperature. Central brains are removed from the cuticle in 1X PBS, carefully preserving brain surface structures, and washed with 1X PBS. Isolated brains are incubated in blocking buffer for 1 hour (1X PBS, 5% goat serum, 4% Tween 20) then probed in primary antibody overnight at 4°C. Brains are washed 3 × 30’ in 1X PBS and probed with appropriate fluorescently labeled secondary antibodies for 45’ at RT (1:200, Invitrogen). Brains are washed 3 × 45’ in 1X PBS and mounted on glass slides using DakoCytomation Fluorescent Mounting medium (Dako, Denmark). Brains are mounted on glass slides with ~40 um posts then covered with coverslip and sealed.

Whole animal Pharmacokinetics

At 0, 1, 2, 4, 8 and 16 hours hemolymph injected whole animals are quickly frozen on dry ice and then crushed in a microfuge tube in 250 uL 0.1% SDS and spun for 1 minute at room temperature. Repeat crush and spin times one. Samples are diluted 10X in 0.1% SDS, vortexed, centrifuged and 100 uL placed in a 96 well fluorimeter plate wells. Fluorescent units are determined using a TECAN Spectrafluor Plus (Männedorf, Switzerland) fluorescence reader or Spectra-Max M2 by Molecular Devices (Sunnyvale, CA) for FITC (ex/em:485/535) or RhoB (ex/em:535/595). All samples are measured in the linear range of a standard curve for each fluor.

Brain-specific dye capture

Rhodamine B (Sigma, R6626) is dissolved in H2O at 2.5 mg/mL and brought to neutral pH. Sibling animals of above flies are decapitated, and brains rapidly dissected (< 90 seconds) from the cuticle, trachea and fat body in 1X PBS. With single forceps tip brains are washed once in 1X PBS and placed in a fluorimeter plate well containing 50 uL 0.1% SDS. Brains are allowed to dissociate over 30 minutes and the dye released from brain samples is measured using appropriate filters as above. Average values of dye retained in CNS tissue are determined after subtracting the background from SDS alone. (Note isolated brains from flour-uninjected animals contain insignificant intrinsic fluor signal.) Statistical error is calculated based on the number of brains used for each sample, as the dynamic range of the signal varies depending on the fluor used. One brain per well can be used for RhoB, and brain specific dye capture is depicted as relative fluorescence units using standard deviation for statistical error (Fig. 2B). For the screen and rescue (Fig. 2B and and5E)5E) RhoB data is shown as normalized values for ease of comparison across genotypes. BODIPY-prazosin (B-Prz, Invitrogen B-7433) is dissolved in 100% DMSO at 2 mM and mixed with dextrans in H2O prior to injection for a final concentration of 1 mM B-Pz and 25 mg/mL 10 kDa Texas Red Dextran (Invitrogen D-1863). B-Prz provides a more limited dynamic range than RhoB, thus 10 brains are pooled per experimental replicate and standard error of the mean is used for statistical error.

Figure 2
Mdr65 promotes efflux of xenobiotics from the brain
Figure 5
Mdr65 Localizes specifically to the SPG

Drug efflux screen

P-element lines resident in the coding region of ABC B and C genes were collected from public sources (Bloomington, Kyoto, Szeged see Flybase http://flybase.bio.indiana.edu/). Lines tested were: WT (Canton S), a c00522 (Mdr50), b SZ4090 (CG1824), c SZ EP3387 (CG4225), d f03674 (CG3156), e EY11060 (CG7955), f SZ-3972 (Mdr49), g KG08723 (Mdr65), h EY13911 (CG5789), i SZ430 (CG14709), j EY09703 (CG4562), k KG04612 (CG11898), l KG08719 (CG7806), m EY11919 (CG6214), n f05095 (CG8799), o KG04706 (CG 31793), p e00744 (CG5772/cyo) and q f01338 (CG7627). Adult animals were injected with 1.25 mg/ml RhoB dye in water at pH 7.0. At 4 hours, whole animals were frozen for whole animal analysis (above), whereas sibling animal brains are dissected and CNS fluorescent dye capture is determined (as above).

Detailed pharmacokinetic analysis

All animals are injected with a mixture of 1.25 mg/mL RhoB and 25 mg/mL 3 kDa FITC dextran (Fig. 2D) (Invitrogen D-3306).

Cell-based efflux assay

HEK293T cells (generously provided by Dr. Warner Greene, Gladstone Institute, UCSF) were transfected with plasmid DNA using Lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s instructions. At 24 hours post-transfection, cells were harvested and counted, and 3×105 cells were incubated in 500 ng/mL rhodamine 123 (Sigma, R 8004) for 30 min in 5% CO2 at 37°C. Intracellular fluorescence was measured on a FACScan flow cytometer (BD Biosciences, San Jose, CA) in channel 2 (FL2, lmax 585 nm) on a logarithmic scale. Statistical analysis was accomplished using a paired t-test P <0.05.

Analysis of PMdr65 Insertion

Inverse PCR (iPCR) was performed on chromosomal DNA (Sullivan et al., 2000). PCR bands from each end of the chromosome were cloned and sequenced confirming the location for PMdr65 (KG08723) in the 8th exon of the Mdr65 gene at nucleotide 6236199 on chromosome III. Primers for RT PCR analysis were designed from the surrounding genomic sequence. Drosophila head RNA was isolated (Sullivan et al., 2000) and reverse transcription (RT) was accomplished with a unique RT primer. RT PCR was done under standard conditions with 30 cycles and products run on 1% agarose gels and stained with ethidium bromide.

Gene cloning of Mdr65

Mdr65 was PCR amplified from EST (RE14657, DGRC) using pfx DNA polymerase (Invitrogen). The 5’ PCR primer included an upstream CACC sequence to promote directional cloning into a pENTR/D-TOPO cloning vector (Invitrogen). Correct insertion orientation and primary nucleotide sequence (3906 bps) was confirmed by sequencing the entire ORF. A single amino acid change (G to D) was noted at A.A. 1190. The entire ORF was moved into a UAS controlled Drosophila Gateway construct, pTWG, containing a GFP tag at the C-terminus by in vitro recombination and confirmed by restriction digestion. (Drosophila Gateway cloning collection, Carnegie Institution, Baltimore, MD). Standard transgenic methods were used to make stable UAS inducible transgenic transposon insertions into the Dm genome (Sullivan et al., 2000).

Gene cloning of MDR1/Pgp

Human MDR1/Pgp was PCR amplified from a pcDNA-5-FRT construct furnished by the Kroetz laboratory using the same methodology as above for Mdr65. Correct insertion orientation and primary nucleotide (3840 bps) sequences for MDR1/Pgp was confirmed by sequencing the entire ORF. The MDR1/Pgp pENTR/D-TOPO construct was then moved into the pTW vector for transgenic expression in Dm (Drosophila Gateway cloning collection). As above, standard transgenic methods were used to make stable UAS inducible transgenic transposon insertions into the Dm genome.

Western Analysis

Western analysis was accomplished with standard 10% PAGE gels blotted onto PVDF membranes (Amersham). Primary antibody hybridization using 1:100 C219 MDR1/Pgp Antibody (Invitrogen), 1:500 GFP monoclonal antibody (Invitrogen) or 1:50 affinity purified Moody Beta antibody (Bainton et al., 2005) was done using a Biorad Mini-gel Western protocol. Visualization of bands was accomplished by incubation with anti-rabbit alkaline phosphatase-conjugated secondary antibody and ECL solution. Mdr65-GFP/SPG-Gal4 double homozygote animals (GxM/GxM) express approximately 8 times as much Mdr65-GFP as double heterozygotes (GxM) as compared by serial dilutions into whole animal crude extracts (data not shown).

Confocal analysis

Confocal images are acquired using a Zeiss LSM-510 (Thornwood, NY) as previously described (Bainton et al., 2005). Laser and detector gain settings for fluorescent background noise are defined using brains with no primary antibody exposure and/or PMdr65 (an Mdr65 loss of function allele). At the coverslip interface, the brain is slightly pressed against the glass providing a flat brain interface with widths of 10–20 um. This preparation provides highly reproducible patterns of Moody staining that allows for proper anatomic identification of dorsal-ventral brain orientation, and overall quality of the brain preparation. As the BBB is a continuous surface around the Dm CNS, the depth of confocality can be changed to find a cross sectional image. To observe a tangential section, we follow the edge of the brain to its greatest extent laterally. This provides the highest resolution of the apical-basal polarization of the BBB epithelia.

Cytotoxicity Assays

Vinblastine (Sigma, V1377) doses were titrated to sustain animal viability (defined by an LD <5% after overnight exposure). Control animals were injected with 3 kDa FITC dextran. Experimental conditions included 3.3 and 6.6 mM vinblastine in water. Brains were dissected from live animals after overnight incubation, with two brains per well for each fluorescent measurement to increase measured signal.

Results

Live Assessment of Chemical Partition at the Dm Retina

To study drug transport physiology in vivo, we inject fluorescent small molecules into the hemolymph of white1118 null (w) flies and visualize drug distribution throughout the animal by following fluorescent signal (Bainton et al., 2005). Because the Dm CNS includes the BBB-protected retinal space (Fig. 1A), xenobiotic penetration of the barrier can be observed in live flies by looking through the cornea at chemical fluors trapped in the retina (Bainton et al., 2005; Banerjee et al., 2008). The white mutation enhances the visibility of the injected dyes by eliminating dark retinal pigments that block scattered light. In previous work, we discovered Moody, a G-protein coupled receptor that localizes to and regulates paracellular border function of the SPG (Daneman and Barres, 2005; Schwabe et al., 2005). Numerous highly charged fluorescent dyes or large molecular weight dextrans injected into the hemolymph compartment are excluded from the retina of w wild-type (w WT) over hours and days but infiltrate w moody null flies within a few minutes of injection (data not shown). In the example shown in Figure 1B, at 4 hours post injection, FITC salt (F) is excluded from the retina of live w WT animals (top, left). Note the distinct high contrast fluorescent signal at the edge of the cornea (black triangles) demarcating the hemolymph and CNS compartments (also shown in cartoon image, Fig. 1A, black arrow). The hemolymph exclusion line (HEL) is a consequence of differential signal intensity between hemolymph passing near the outer segments of the retina (i.e. the humoral space) and signal that originates from inside the retina (i.e. CNS space) (See arrow Figure 1A). In a FITC injected w moody null animal no HEL is observed, as FITC dye infiltrates the retina (top, right) and the central brain (data not shown). By contrast, many lipophilic dyes that are good ABC transporter substrates, like Rhodamine 123 (Rho123), are excluded from the retina in both w WT and w moody null flies (Fig. 1B, bottom). Thus, Rho123 partitioning is not impaired by a significant defect in paracellular barrier function, suggesting that Dm has additional mechanisms for isolating the CNS.

Because Rho123 is an efficient substrate for the vertebrate ABC transporter MDR1/Pgp, (Nag, 2003; Loscher and Potschka, 2005b) we tested whether its exclusion by the Dm BBB is affected by known MDR1/Pgp transport inhibitors. When Rho123 is co-injected into w WT flies with cyclosporine A (CsA) or GF120918 (GF) (Loscher and Potschka, 2005b), increased penetration of the retina by Rho123 is observed, with CsA having a stronger effect than GF (Fig. 1C, left column middle and bottom). Neither transport inhibitor breaks down the paracellular diffusion barrier, as 10 kDa Texas Red dextran (TRD) is still completely excluded from the CNS (Fig. 1C, right column). Thus, active transport appears to be necessary for maintenance of the Dm BBB and is functionally separable from the paracellular diffusion barrier.

A Screen for BBB Active Transporters

The effect of CsA and GF on Rho123 partition suggested that one or more ABC transporters play a role in maintaining chemical isolation at the Dm humoral/CNS barrier. This assertion is supported by the exhaustive literature demonstrating that ABC transporters are highly expressed at many chemoprotective interfaces, including the BBB in vertebrates, and that altering their function, whether chemically or genetically, can affect xenobiotic partition (Loscher and Potschka, 2005b; Sarkadi et al., 2006). In mammals ABC genes occur in seven families (A through G) with a total of about 50 genes in humans. Interestingly, while ABC gene sequence and subfamilies are highly conserved from flies to humans, the specific roles of most genes are unknown (Dean et al., 2001) (Gerrard et al., 1993). The major xenobiotic transporter classes are the B (n=11), C (n=12) and G (n=5) families. Unfortunately, because the best studies of ABC transporters in vitro and in the animal are limited to a few genes, it is not known whether they function as a complimentary system (i.e. posses chemical redundancy or compensation) or operate in chemical isolation. However single gene loss of function can have a profound effect on chemical partition, as ABC B1 (MDR1/Pgp), ABC C1 (MRP1) and ABC G2 (BCRP) knockout mice demonstrate large defects in drug partition at the BBB when challenged with xenobiotics (Sarkadi et al., 2006). Hence it is possible to consider experiments that phenocopy functional physiology of ABC transporters at the Dm BBB. Unfortunately identifying such transporters purely by comparing primary sequence across phyla is not possible, thus we focused our efforts on a reverse genetic screen of mutant alleles of Dm ABC genes.

Sequence comparison between human ABC genes and the Dm genome identified 22 highly homologous genes (B (n=10) and C (n=12), http://blast.ncbi.nlm.nih.gov/Blast.cgi). Using fly database (http://flybase.bio.indiana.edu) searches, we identified P-element lines that interrupted the coding region for 17 (7 class B and 10 class C) of the 22 ABC transporter genes (see methods). All P-element lines were white plus (w+), precluding use of the live visual assay for small molecule penetration screening. Therefore, dye penetration of the BBB was assessed by dissecting brain tissue from fluor-injected animals and directly measuring CNS dye capture (see methods). The lipophilic dye Rhodamine B (RhoB) used in the screen is a substrate for ABC transporters and is highly fluorescent in aqueous environments. RhoB is also well tolerated by flies and has a bioelimination half-life of 4 hours, which is practical for quantitative assays of brain efflux (Fig. 2A). RhoB was injected into the hemolymph of twenty individuals from each P-element line. At 4 hours post-injection, fluor content was determined for either dissected brain tissue alone or for whole animals (Fig. 2B). Whole animal fluor content showed little or no significant difference among mutant lines (black bars). However, one line (g) demonstrated a high relative brain-specific (colored bars) RhoB accumulation.

This line, referred to here as PMdr65, contains a P-insertion on the third chromosome in a previously described putative ABC transporter gene, Mdr65 (Wu et al., 1991; Bosch et al., 1996). The BBB phenotype of PMdr65 is retained after a five generation outcross. PCR analysis of PMdr65 genomic DNA demonstrates transposon sequences resident in the 8th exon of the Mdr65 coding region, and a precise excision of the P-element restores WT drug transport (data not shown). RT-PCR analysis of PMdr65 RNA demonstrates an altered transcript consistent with P sequences disrupting the putative Mdr65 transporter ORF (Supplementary Data Figure 1A). This evidence indicates that increased brain-specific retention of RhoB results from an alteration of Mdr65 gene expression. Mdr65 exhibits 42% sequence identity to MDR1/Pgp, the major ABC transporter found at the mammalian BBB, and the two proteins are predicted to have similar secondary structure (data not shown).

To confirm that Mdr65 encodes an ABC transporter with xenobiotic efflux properties similar to MDR1/Pgp we cloned the Mdr65 ORF by PCR, added a C-terminal GFP tag, and tested transport function of the resulting Mdr65-GFP fusion in transiently transfected HEK cells (Fig. 2C). Mock transfected cells lack sufficient endogenous ABC transporters and accumulate Rho123 when placed in dye-containing media. In contrast, cells expressing either Mdr65-GFP or mammalian MDR1/Pgp accumulate significantly less Rho123, indicating efficient active transport of the dye out of the cytoplasm (Fig. 2C).

Mdr65 Loss of Function Animals Are Deficient in Brain-specific Xenobiotic Efflux

In order to determine whether the increased brain accumulation of RhoB in Mdr65 mutants is due specifically to effects on the active transport barrier, we co-injected WT and PMdr65 flies with RhoB and 3 kDa FITC dextran, a large MW dye conjugate that cannot be effluxed by ABC transporters. The total amount of each dye in whole animals or dissected brains was measured at various times after injection. As expected, RhoB is eliminated from the body within hours while dextrans persist for days or weeks (Fig. 2D and data not shown). Whole animal controls show that dosing and elimination of RhoB are not affected by the PMdr65 mutation (Fig. 2D, lower panel), and visual inspection through the body cuticle revealed no gross differences in fluor distribution in the animal (data not shown). Furthermore, brain accumulation of 3 kDa FITC dextran remained near background levels in both WT or PMdr65 animals (Fig. 2D, upper panel, green lines), indicating that the Mdr65 mutation does not significantly disturb the paracellular diffusion barrier. Indeed, the PMdr65 BBB was indistinguishable from WT relative to all highly charged small molecules tested (data not shown). Finally, brain levels of RhoB (red lines) were similar between fly lines at early time points, showing that the Mdr65 mutation does not affect initial brain penetration by RhoB, which was confirmed by live retinal assays (data not shown). At 4, 8 and 16 hours post-injection, however, PMdr65 flies exhibited significantly higher brain levels of RhoB than WT flies, suggesting the mutant flies had markedly reduced RhoB efflux from the brain. To confirm a role for the Mdr65 gene in BBB localized xenobiotic transport function, we produced an sub-perineural glia (SPG)-specific Mdr65 hypomorphic allele by crossing an SPG Gal4 driver (shown in Fig. 3) to an inducible Mdr65-specific RNAi (Dietzl et al., 2007). We verified BBB-specific Mdr65 reduction by methods discussed in Figure 5 (data not shown). Like PMdr65 individuals, these animals are deficient in brain-specific RhoB transport when compared to WT (Fig. 2E). These findings parallel the brain-specific pharmacokinetics of MDR1/Pgp substrates in Mdr1a-Mdr1b knockout mice demonstrating that the contribution of Mdr65 to BBB drug efflux function in Dm is similar to that of MDR1/Pgp in vertebrates. (Schinkel, 1997; Schinkel et al., 1997)

Figure 3
Confocal Identification of the Dm humoral/CNS interface

Evaluating Barrier Physiology at the Sub-perineural Glia in Adult Drosophila

Previously, the sub-perineural glia was identified as the potent CNS diffusion barrier layer in EM studies in other insects and in Drosophila larva (Treherne JE, 1972; Carlson et al., 2000; Stork et al., 2008). In recent work, we showed that a novel orphan GPCR, Moody, is expressed exclusively in the SPG layer of larva brains and nerves (Bainton et al., 2005). In order to correlate in vivo assays at the retina (Figure 1) with functional changes at the barrier we developed methods to simultaneously identify the anatomic localization and physiologic properties of the humoral/CNS interface in Dm adults. Fixation is carried out in situ to preserve BBB anatomy susceptible to damage during dissection of the exoskeleton (see methods). To accomplish this, the proboscis is removed to allow access of fixative into the brain. While the BBB anatomy around parts of the central brain is distorted by this procedure, subsequent dissections and mountings enable reproducible visualization of the BBB in the area of the lobular plate, the optic chiasm and retina (see Figure 1). The retina is often removed during mounting for better position of the brain on the slide. By co-staining brains expressing Nrv2-Gal4, a gene whose expression is limited to neurons and cortical glia (Pereanu et al., 2005), we show that Moody antibody staining in adults is peripheral to the CNS (Fig. 3A). Higher resolution images confirm that the Moody GPCR is superficial to cortical glia, discrete to the SPG and thus specifically demarcates the Dm BBB border in situ (Fig. 3A, inset).

A hallmark of BBB physiology is the compact cellular localization of chemoprotective systems that include tight junctional barriers and ABC transporters (Fig. 1A). To understand how specific gene expression at the BBB interface generates cell autonomous physiologic function, we employed methods to control gene expression in the SPG while concurrently evaluating physiologic outcomes at that interface. Targeted gene expression is achieved using the two transgene method (Brand and Perrimon, 1993). The transcriptional activator Gal4 was put under the control of the Moody transcriptional enhancer to produce a highly specific Gal4 expression pattern specific to the sub-perineural glia layer (SPG-Gal4) (Stork et al., 2008). Moody has two isoforms, alpha and beta, that completely colocalize (Bainton et al., 2005). SPG-Gal4 specific gene expression of a GFP tagged Moody alpha construct coincides perfectly with Moody beta antibody staining (Fig. 3B and inset), verifying that gene expression can be directed exclusively to the SPG cell layer in adult flies. This expression specificity confirms that Mdr65 RNAi-induced loss of function in the SPG is targeting a BBB localized chemoprotective function of Mdr65 (Fig. 2E).

Localized physiologic properties of the BBB are evaluated by combining fluorescent chemical reporters and the above anatomic methods. Standard confocal samplings methods yield a detailed cross sectional image of the humoral interface, demonstrating that the barrier is closed to 10 kDa dextrans along the entire periphery of the brain (Fig. 3C). Indeed, these barrier properties correlate well with dextran diffusion experiments at the vascular endothelium of the vertebrate BBB (Ballabh et al., 2004). Note that some dye is trapped by a more superficial cellular layer known as the perineural glia (PG) (Stork et al., 2008), resulting in a gradient along the brain surface (Fig. 3C, inset). However, while the PG is completely infiltrated with dye, no fluorescent signal transits the SPG cellular barrier layer (Fig. 3C histogram), identifying the SPG as the tightest diffusion barrier at the humoral interface. In situ localization of dextran penetration correlates well with live retinal assays of BBB function (Fig. 1) and fluor content of brains in quantitative dissection assays (Fig. 2D). Taken together, these data show that the Dm SPG in adults is a CNS ensheathing-epithelium distinct from other glial layers with tight-diffusion barrier properties similar to the vascular endothelium.

It is important to note that the vertebrate BBB is complex, comprised of multiple cell types (i.e. capillary vascular endothelium, pericytes, a basement membrane, and closely associated astrocytic glia) (Abbott, 2005). Furthermore it participates in numerous cellular physiologies including hemodynamic neurovascular coupling, neuro-immune function, extracellular matrix interactions, neurotransmitter inactivation and of course chemical protection (Zlokovic, 2008). The integration of these physiologies requires a dynamic barrier, as it must respond to changes in metabolic requirements as well as to exogenous threats, such as xenobiotics and infectious agents. Similar to vertebrates, the Dm BBB has multiple cell types at the CNS/humoral interface. Moving outward from neurons the Dm barrier includes two glially-derived cell layers (sub-perineural and perineural, Fig. 3C), an associated immune cell layer and a fat body layer (data not shown). The primary focus of this work is the physiologic similarity of the vascular endothelium in vertebrates and the sub-perineural glia in Dm. However the additional cellular complexity of the Dm BBB may offer ways to model cellular interactions in regulation and control of BBB physiology including sensing and responding to the metabolic needs of neurons, immune cell transcytosis, and remodeling after CNS injury. Thus, while the Dm BBB is not anatomically super-imposable on that of vertebrates, this work establishes a framework upon which to build an integrated model of BBB physiology and to discover and test regulatory hypotheses of CNS chemical protection.

Mdr65 Drug Partition Function Localizes to the CNS/humoral Interface

To better understand chemo-protective deficits of Mdr65 loss of function animals, we compared the chemical partition of a number of fluorescently tagged MDR1/Pgp substrates in w WT flies and w PEx8 flies using the live retinal assay. PEx8 is a loss of function allele of Mdr65 derived from an imprecise excision of PMdr65 (Supplementary Figure S1A). We found that BODIPY-labeled Prazosin (B-Prz) partition was affected by loss of Mdr65 function (data not shown). Co-injection of TRD and B-Prz into w WT flies and w PEx8 flies confirmed that the loss of Mdr65 function in PEx8 flies leads to increased levels of B-Prz in both the brain and retina but leaves the paracellular diffusion barrier intact (Fig.4 A,B). These data are directly visualized in CNS tissue by confocal microscope sections of whole dissected Dm brains. Brains from hemolymph injected adult animals demonstrate clear penetration of B-Prz throughout the CNS parenchyma in PEx8 animals but tight exclusion from the brains of WT animals (Fig. 4C). A striking feature of these images is the tight juxtaposition of B-Prz signal (green) near the diffusion barrier (red) in WT flies, suggesting that the efflux transport barrier, like the diffusion barrier, is closely localized at the humoral/CNS interface (Fig 4C, w WT top panels and small panel b). In contrast the transport barrier is absent in PEx8 flies (Fig.4C, compare small panel b to e). Thus, brain-specific Mdr65 drug partition function localizes to the humoral interface. Furthermore, the close proximity of the diffusion and transport barriers in the SPG recapitulates the simultaneous manifestation of the diffusion and transport barriers in the vertebrate vascular endothelium (Figure 1).

Figure 4
Mdr65 promotes drug exclusion at the SPG

Mdr65 Is Specifically Localized in the Dm CNS

The distinctive BBB exclusion pattern of B-Prz suggested that Mdr65 transport function is located in the SPG. Indeed, Mdr65 mRNA is known to be highly expressed in the brain surface glia of Dm and regulated by glial-specific transcription factors (Freeman et al., 2003). To ascertain the precise location of endogenous Mdr65, we combined newly identified Mdr65-specific antibody reagents with the above methods for understanding BBB structure and physiology. Thus we bring together three types of reagents: antibodies that specifically recognize ABC transporters in the cell membrane, enhancer traps specific to the different cellular layers of the Dm BBB and fluorescent dextrans that demonstrate the diffusion constraints of the cellular junctions of the BBB. Together these tools allowed us to specifically visualize individual cellular layers of the very compact humoral/CNS interface.

To this end, we confirmed that C219, an MDR1/Pgp-directed monoclonal antibody, specifically recognizes Mdr65-GFP by Western analysis of whole fly heads (Supplementary Data Figure S1C) (Kartner et al., 1985; Riordan et al., 1985; Bosch et al., 1996). Cross-sectional images of adult brains co-stained with Moody and C219 antibodies demonstrate continuous co-localization of Moody and Mdr65 at the periphery of the CNS (Fig. 5A, top row). Higher resolution images obtained by repeated confocal sampling show that Mdr65 is predominantly apical to Moody all along the SPG/humoral interface (Fig. 5A, middle row and inset histogram). Brain-surface images reveal different patterns for Moody and Mdr65 in the X–Y dimension, suggesting different restricted localizations at the humoral interface. (Fig. 5A, bottom). We further refined relative localization of the two signals by labeling SPG nuclei with GFP. Since SPG nuclei are 500–800 nm in thickness, the distance between the apical and basal membranes of the SPG is increased near the nucleus (Fig. 5B). Under such conditions Moody is clearly localized to the basal side of nuclei, while Mdr65 resides on the apical side. To determine whether Mdr65 and Moody are localized to the same cell, we stained animals expressing low levels of SPG-specific Mdr65-GFP with Moody antibodies and found that Mdr65-GFP is apical to Moody with little or no overlap (Fig. 5C, top panel). When the same animals are stained with C219, the GFP and C219 signals are perfectly coincident, indicating that Mdr65 co-localizes with Mdr65-GFP and therefore resides in the apical interface of the SPG (Fig. 5C, lower panel). Finally, C219 staining of WT and PMdr65 brains demonstrates greatly reduced signal at all localizations along the BBB interface in PMdr65 animals, confirming that PMdr65 is a loss of function allele of mdr65. (Fig. 5D, middle panel)

SPG-specific Expression of Mdr65-GFP or Human Pgp Rescues Transport Function

To confirm that Mdr65 loss of function is responsible for functional perturbations in BBB-specific xenobiotic efflux, we showed that expression of Mdr65-GFP in the SPG rescues the RhoB transport phenotype. Targeted gene expression was achieved using an SPG-Gal4 transgene (G) driving the expression of UAS-Mdr65-GFP (M). Brain-specific efflux of RhoB in a WT background is only modestly affected by a single GxM transgene cross (Figure 5E, column 2). However the same cross completely restores WT transport function in an Mdr65 null (PEx8) background (Figure 5E, column 6). Apical SPG localization of Mdr65-GFP was confirmed in rescued animals by confocal microscopy (Fig. 5F). Thus Mdr65-GFP expression at the humoral interface is sufficient to restore efflux transport of small molecule fluors, indicating that a role of Mdr65 in CNS protection is localized to the SPG. These data suggest Mdr65 plays a cell autonomous role in xenobiotic protection at the fly BBB similar to the proposed role of other powerful ABC transporters at the VE of vertebrates (Sarkadi et al., 2006). If so then Mdr65 loss of function should be complemented by a similarly functioning vertebrate gene. We tested this hypothesis by driving the expression of human MDR1/Pgp in the Dm SPG (G) with a UAS-MDR1/Pgp construct (P) and confirmed protein expression in western blots probed with C219 antibody (Supplementary Data Figure S1D). G×P animals expressing low levels of MDR1/Pgp in a WT background had no effect on RhoB brain retention, (Figure 5E, column 3). Animals carrying, but not selectively expressing the P transgene in an Mdr65 null (PEx8) background, could partially rescue the mutant phenotype, likely secondary to leakiness of the transgene construct (Fig. 5E, column 7). However a G×P transgene cross in the mutant background fully restored WT levels RhoB transport (Fig. 5E, column 8). Thus evolutionarily distant, but physiologically similar xenobiotic transporters can promote similar levels of chemical protection function across species.

SPG Mdr65 Levels Alter BBB Susceptibility to Cytotoxins

Drug transport studies in vivo and in vitro suggest that ABC transporters are modular units and that efflux function is proportional to transporter expression levels (Dohgu et al., 2004; Loscher and Potschka, 2005a; Bachmeier et al., 2006; Sarkadi et al., 2006). To determine whether similar properties would manifest in vivo at the humoral/CNS interface of Dm, we tested the effect of Mdr65-GFP overexpression on RhoB partitioning. Transporter gain of function conditions were achieved using double homozygotes of the G and M transgenes (GxM/GxM) in a WT background. Mdr65-GFP expression is several fold greater than native Mdr65 expression in WT animals (Supplementary Data Figure S1C), and all Mdr65-GFP transporter localization is at the apical interface of the SPG (data not shown). Brain-specific RhoB content is significantly decreased in GxM/GxM lines relative to WT (Fig. 6B). Thus, increasing or decreasing the level of ABC transporters in the Dm SPG can alter xenobiotic partition at the humoral/CNS interface in much the same way that changes in MDR1/Pgp expression alters xenobiotic penetration into the cytoplasm of isolated cultured cells (Chaudhary and Roninson, 1993).

Figure 6
Mdr65 levels change the sensitivity of the Dm BBB to cytotoxic drugs

Pharmacokinetic models predict that altering the level of ABC transporter expression or localization will shift the chemical partition of drugs in the BBB-protected space (Schinkel, 1999). Since Mdr65 resides in the apical membrane of the SPG in flies, the cytoplasm of SPG cells is included in the BBB-protected zone, and varying the level of Mdr65 should alter the sensitivity of SPG cells to ABC transportable cytotoxins in a predictable manner. To test this hypothesis, we studied the effect of the anti-microtubule agent vinblastine (VB) on SPG cell function. VB was chosen because it is transported by Mdr65 in vitro (data not shown). Since breakdown of the cytoskeleton affects the integrity of paracellular junctions, SPG cell function can be assayed by monitoring the passage of large MW dextrans from the hemolymph into the CNS. In the absence of VB, the paracellular diffusion barrier is intact, and the 3 kDa FITC-dextran is entirely peripheral to the brain (Fig. 6C or D, data not shown). When WT animals are co-injected with 3.3 mM VB and FITC-dextran, a small but significant amount of FITC signal leaks into the CNS (Fig. 6C left). Under the same conditions, Ex8 brains accumulate FITC-dextran internal to the SPG more than WT brains, indicating that mdr65 loss of function increases the sensitivity of SPG cells to VB (Fig. 6C, right and data not shown). Similar results are obtained when Mdr65 loss of function is directed to the SPG by Mdr65 RNAi (Fig. 2E), thus cell autonomous Mdr65 function provides some measure of chemoprotection at the barrier interface (data not shown.) We performed the same experiment on mdr65 overexpressors using 6.6 mM VB. These animals accumulated significantly lower levels of FITC-dextran than WT (Fig. 6D, GxM/GxM). In vivo retinal dye penetration studies corroborated the results obtained above by direct assessment of retinal fluor content (Fig. 6C and D, lower panels). These results indicate that anatomically selective changes in Mdr65 can lead to altered levels of chemical neuroprotection and suggest that modulation of individual components of the BBB can be exploited to adjust the entry of specific drugs into the brain.

Discussion

The central nervous system is protected from the influence of the external environment by a blood-brain barrier. This cellular layer uses two properties to promote neuroprotection: a tight diffusion barrier and a complex array of transcellular transporters. Even though both properties are essential for proper humoral/CNS separation, little is known about their functional integration and regulation. In the Drosophila BBB tissue layer, the SPG, strong diffusion barrier properties had been previously identified, but the nature of its xenobiotic barrier had not been established. In this paper we characterize both physiologic aspects of the adult animal barrier and describe a novel system for the study of brain-specific small-molecule transport physiology. We combine in vivo physiologic assays for drug barrier function, and forward genetics to identify Mdr65 as an essential BBB transporter. Mdr65 loss of function leads to increased accumulation of ABC transporter substrates in the brain and increased sensitivity to cytotoxic xenobiotics. These studies suggest functional parallels between Mdr65 and the human MDR1/Pgp transporter, and together show strong evolutionary conservation of cell structure and chemoprotective mechanism in vertebrate and invertebrate CNS/humoral interfaces.

Chemical protection of the brain is a complex process involving many overlapping physiologic systems and thousands of genes (Abbott, 2005; Sarkadi et al., 2006; Zlokovic, 2008). While recent advances in genomic and proteomic profiling of BBB components promise to provide a detailed description of the molecular players in BBB physiology, understanding how these components act in concert in a given environment remains a difficult problem for vertebrate systems to solve (Calabria and Shusta, 2006). Integrative physiology is a discipline that promotes the use of appropriate model organisms to test physiologic function of particular genes and interacting genetic systems (Dow, 2007). A powerful ambition of this approach is to find an experimental system advantageous for interpretation of gene function in different functional contexts (i.e. in the whole animal and/or cell-autonomous/tissue-based circumstances) (Yang et al., 2007). We chose to focus our work in Drosophila where a glial-dependent blood-brain barrier chemically insulates an open circulatory system from the retina, central brain and peripheral nerves (Carlson et al., 2000; Stork et al., 2008).

Previously, we discovered and began to characterize the BBB specific function of a Dm orphan GPCR, Moody, that localizes with junctional complex components and likely controls diffusion barrier tightness through signals to the actin cytoskeleton (Bainton et al., 2005; Schwabe et al., 2005). Moody’s functional association with cellular junctions demonstrated for the first time the existence of hierarchichal control systems designed to direct specific aspects of BBB physiology. Interestingly, varying degrees of hypomorphic mutants in Moody demonstrate a range of phenotypes from subtle behavioral changes (i.e. drug responses) to outright disruption of the diffusion barrier in null animals. As GPCRs transmit information from external cellular stimuli as varied as photons and hormones, Moody’s discovery suggested the possibility that chemoprotective sensors may localize to and provide critical moment to moment evaluation and adjustment of barrier performance. However to pursue the control systems of chemical protection physiology, additional molecular and cellular components of the Dm CNS xenoprotective interface had to be established (Figure 1).

ABC transporters control localized pharmacokinetic penetration of drugs and are highly homologous between species thus it was logical to pursue their role at the Dm BBB. Unfortunately, direct sequence comparisons of human MDR1/Pgp or Mrp1 to Dm ABC B and C gene family members, respectively, did not yield any obvious candidates for specific chemoprotective genes (Dean and Annilo, 2005). To unravel neuro-chemical protective function, we performed a reverse-genetic, physiologically-based screen that takes advantage of large collections of pre-existing mutants in many Dm genes and identified PMdr65, a loss of function allele of an ABC B transporter (Figure 2). To confirm the PMdr65 mutant’s functional relevance to the CNS, we devised additional quantitative and in vivo drug partition assays that address transporter-specific neuroprotective processes (Figures 3 and and4)4) and localized Mdr65 expression and function to the apical interface of the Dm BBB (Figure 5). Furthermore human MDR1/Pgp expressed at the Dm BBB could similarly rescue drug transport, thus MDR1/Pgp can function cell autonomously to protect a CNS interstitial space. These data show that at least one ABC transporter in Dm performs BBB specific duties similar to vertebrate MDR1/Pgp (Schinkel, 1999) and suggests that the unique demands of CNS chemoprotection may select for transporters that are tuned to neural barrier requirements, even though very large evolutionary distances obscure the functional relationship of specific genes.

Coincident localization of the diffusion and xenobitotic transport barriers (Figure 4C) demonstrated that the Dm BBB combines vertebrate-like drug exclusion mechanisms to maintain a chemical barrier for the brain. This is an ideal setting to test the inter-relationship of chemical protection components at the cellular, organ and organismal levels (Strange, 2007). For example in vertebrates MDR1/Pgp overexpression specifically promotes chemotheraptic drug resistance in cancer cells (Gottesman et al., 2002). Here the quantity of an individual transporter at the cell membrane can alter the localized pharmacokinetics of a toxin by reducing partition into cells through increased efflux. However, at the BBB, the same gene functions in a complex cellular environment where xenobiotic protection has the potential to be dependent on not only the content of a single transporter, but also cell-type specific expression, spatial localization in a polarized cellular interface, additional transporters and other localized pharmacokinetic processes like diffusion barriers and metabolic enzymes (Sarkadi et al., 2006; Zlokovic, 2008). A strong drug barrier like the BBB can only function appropriately when all of these properties are manifested and correctly integrated. In this paper we show that increased quantities of BBB-specific Mdr65 induces CNS specific super-protection to cytotoxic substrates (Figure 6B). This is dependent on transporter localization, since several biologic tags to Mdr65 that prevent apical membrane association abrogate super-protection and rescue of xenobiotic sensitivity in Mdr65 nulls while exhibiting otherwise normal expression (data not shown). Thus a single overexpressed transporter can protect both an individual cell and, if properly localized, an entire viscous space like the CNS from drugs or chemicals. These data support the prevailing paradigm in vertebrate ABC transporter biology that end organ sensitivity must be matched with transporter type, quantity and discrete localization to promote xenobiotic efflux across cellular interfaces (Sarkadi et al., 2006).

A great advantage of the Drosophila model system is that cell autonomous gain or loss of function can be tested with anatomically directed genetic reagents, an approach that remains a technical challenge in vertebrates. Interestingly, selective, cell-type specific reduction of Mdr65 in the BBB produces a qualitatively similar xenobiotic phenotype to Mdr65 loss of function animals (about 1.7:1, mutant to WT Fig 2 E), thus much of Mdr65’s chemoprotective phenotype is targeted to the SPG. However this RNAi induced chemosensitive phenotype is not as strong as Mdr65 loss of function (2.4:1 mutant to WT Figure 2B), suggesting additional roles for Mdr65 in whole animal small molecule pharmacokinetics. In fact, anatomically specific gene expression profiling demonstrates heightened levels of Mdr65 at other chemoprotective interfaces such as the gut and malphigian tubules (http://www.flyatlas.org/). Thus, like vertebrate MDR1/Pgp, Mdr65 could play a role in broader xenobiotic/drug physiology, suggesting further evolutionary conservation between the way vertebrates and invertebrates organize and regulate chemical protection biology.

Finding innovative solutions to the drug delivery problems presented by the BBB – and indeed by all biological barriers – is likely to require an integrated understanding of the physiological mechanisms that allow barriers to maintain a balance between metabolic homeostasis and chemical protection. A genetic system like Dm offers the opportunity to employ inducible gene reduction systems and thus gain insight into acute responses to drug efflux loss of function, a condition similar to selectively localizing high levels of a transport inhibitor. Ultimately, these methods may be more gainfully applied to multiple, simultaneous gene reductions at the BBB interface. Such epistasis experiments targeting multiple localized small-molecule partition components will be a powerful method to uncover subtle interactions between localized pharmacokinetic control systems. With these tools in hand, future work will focus on systematic characterization of transport interfaces, through genomics or proteomics, and analysis of barrier responsiveness to various neurologic insults including cytotoxic drugs, hypoxia and metabolic stress.

Recent analyses of vertebrate barrier components point to a large number of biological pathways that may be involved in controlling and integrating the various aspects of barrier function (Enerson and Drewes, 2006; Zlokovic, 2008) (Ben Barres, personal communication). However, establishing the relevance of potential gene candidates is difficult without model systems that allow rapid analysis of proposed pathway function (Dow, 2007; Yang et al., 2007). We present a framework for using reverse genetics to build an integrated model of BBB physiology and to discover and test regulatory hypotheses of CNS chemoprotection. In addition this system has shown that simple genetic screens for breakdown of BBB function can identify new and unrecognized genes, like Moody, that are part of the regulatory hierarchy of neuroprotection hinting at modulatable control systems in vertebrate chemoprotection. Indeed, ongoing forward genetic screens have also identified mutants in several Dm genes that are highly homologous to relevant vertebrate BBB genes involved in signaling, stress sensing and establishing and maintaining the structure of the BBB (data not shown). Thus BBB specific genes and processes found in model organisms, particularly Drosophila, could lead to novel insights into the organization and cellular separation of the multiple protective BBB physiologies. These considerations, we believe, make our model system remarkably useful in terms of understanding how ancient and resilient organisms, such as the fruit fly, protect their CNS. Lastly, this approach may promote the identification of common, conserved regulatory pathways that contribute to chemical protection biology and BBB physiology across species.

Supplementary Material

Supp1

Mdr65 genetic locus and molecular analysis:

(A) PMdr65 localization in exon 8 of the Mdr65 gene locus was confirmed by inverse PCR analysis (data not shown). (B) The Mdr65 gene is transcribed in WT and PMdr65 animals as RT-PCR analysis of mRNA demonstrates appropriate sized bands with gene specific oligonucleotide primers distal to the P-insertion (distal to P primers, lanes 2, 3 and 4). Primers that span exon 8 (across P) demonstrate product only in wild type animals. P sequence specific primers demonstrate product only in P or PEx8 lanes (P out). (C) Standard Western blot analysis shows the same blot probed sequentially with C219, anti-GFP and anti-Moody beta antibodies. Samples, derived from whole fly heads, are WT, PMdr65, PEx8 and SPG-Gal4 crossed to UAS-Mdr65-GFP double homozygotes (GxM/GxM). C219 recognizes Mdr65-GFP (top, lane 4). The estimated MW of native Mdr65 is 160–180 kDa. A band of that size is noted in all lanes, but is significantly diminished in the Mdr65 loss function lines (lane 2 and 3). GFP specific antibody confirms the identity of Mdr65-GFP (middle, lane 4). Moody beta antibody is used as a protein loading control (bottom). (D) Standard Western blot analysis shows a blot probed with C219 antibodies. Samples, derived from whole fly heads, are WT, PMdr65, and SPG-Gal4 crossed to UAS-MDR1/Pgp double homozygotes (G×P/G×P). C219 recognizes a new band of the approximate MW of MDR1/Pgp (140 kDa).

Acknowledgements

We thank Kelly Komachi, Owen Hughes, Laura Mitic, Adrian Rothenfluh, and Kaveh Ashrafi for many many helpful comments and editing. We thank Reed Kelso for his technical assistance early in the work. We are very grateful to Ron Vale, Peter Walter, Eric Griffis, Nico Sturrman and Toby Walther for assistance in confocal microscopy. We thank Susan Johns for comparative genomic analysis. We also thank the Kenyon, Blackburn, Fung, and O’Farrell labs for being super neighbors and kind associates. This work was done with the generous support of the NIH (GM081863).

References

  • Abbott NJ. Dynamics of CNS barriers: evolution, differentiation, and modulation. Cell Mol Neurobiol. 2005;25:5–23. [PubMed]
  • Bachmeier CJ, Trickler WJ, Miller DW. Comparison of drug efflux transport kinetics in various blood-brain barrier models. Drug Metab Dispos. 2006;34:998–1003. [PubMed]
  • Bainton RJ, Tsai LT, Schwabe T, DeSalvo M, Gaul U, Heberlein U. moody encodes two GPCRs that regulate cocaine behaviors and blood-brain barrier permeability in Drosophila. Cell. 2005;123:145–156. [PubMed]
  • Ballabh P, Braun A, Nedergaard M. The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol Dis. 2004;16:1–13. [PubMed]
  • Banerjee S, Sousa AD, Bhat MA. Organization and function of septate junctions: an evolutionary perspective. Cell Biochem Biophys. 2006;46:65–77. [PubMed]
  • Banerjee S, Bainton RJ, Mayer N, Beckstead R, Bhat MA. Septate junctions are required for ommatidial integrity and blood-eye barrier function in Drosophila. Dev Biol. 2008;317:585–599. [PMC free article] [PubMed]
  • Bosch I, Jackson GR, Jr, Croop JM, Cantiello HF. Expression of Drosophila melanogaster P-glycoproteins is associated with ATP channel activity. Am J Physiol. 1996;271:C1527–C1538. [PubMed]
  • Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401–415. [PubMed]
  • Calabria AR, Shusta EV. Blood-brain barrier genomics and proteomics: elucidating phenotype, identifying disease targets and enabling brain drug delivery. Drug Discov Today. 2006;11:792–799. [PubMed]
  • Carlson SD, Juang JL, Hilgers SL, Garment MB. Blood barriers of the insect. Annu Rev Entomol. 2000;45:151–174. [PubMed]
  • Chaudhary PM, Roninson IB. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. J Natl Cancer Inst. 1993;85:632–639. [PubMed]
  • Daneman R, Barres BA. The blood-brain barrier--lessons from moody flies. Cell. 2005;123:9–12. [PubMed]
  • Dean M, Annilo T. Evolution of the ATP-binding cassette (ABC) transporter superfamily in vertebrates. Annu Rev Genomics Hum Genet. 2005;6:123–142. [PubMed]
  • Dean M, Rzhetsky A, Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001;11:1156–1166. [PubMed]
  • Demeule M, Vachon V, Delisle MC, Beaulieu E, Averill-Bates D, Murphy GF, Beliveau R. Molecular study of P-glycoprotein in multidrug resistance using surface plasmon resonance. Anal Biochem. 1995;230:239–247. [PubMed]
  • Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblauer S, Couto A, Marra V, Keleman K, Dickson BJ. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature. 2007;448:151–156. [PubMed]
  • Dohgu S, Yamauchi A, Takata F, Naito M, Tsuruo T, Higuchi S, Sawada Y, Kataoka Y. Transforming growth factor-beta1 upregulates the tight junction and P-glycoprotein of brain microvascular endothelial cells. Cell Mol Neurobiol. 2004;24:491–497. [PubMed]
  • Dow JA. Integrative physiology, functional genomics and the phenotype gap: a guide for comparative physiologists. J Exp Biol. 2007;210:1632–1640. [PubMed]
  • Edwards JS, Swales LS, Bate M. The differentiation between neuroglia and connective tissue sheath in insect ganglia revisited: the neural lamella and perineurial sheath cells are absent in a mesodermless mutant of Drosophila. J Comp Neurol. 1993;333:301–308. [PubMed]
  • Enerson BE, Drewes LR. The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab. 2006;26:959–973. [PubMed]
  • Freeman MR, Delrow J, Kim J, Johnson E, Doe CQ. Unwrapping glial biology: Gcm target genes regulating glial development, diversification, and function. Neuron. 2003;38:567–580. [PubMed]
  • Gerrard B, Stewart C, Dean M. Analysis of Mdr50: a Drosophila P-glycoprotein/multidrug resistance gene homolog. Genomics. 1993;17:83–88. [PubMed]
  • Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58. [PubMed]
  • Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature. 1985;316:820–823. [PubMed]
  • Loscher W, Potschka H. Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol. 2005a;76:22–76. [PubMed]
  • Loscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx. 2005b;2:86–98. [PMC free article] [PubMed]
  • Nag S. The Blood-Brain Barrier. Totowa, NJ: Humana Press; 2003.
  • Neuwelt E, Abbott NJ, Abrey L, Banks WA, Blakley B, Davis T, Engelhardt B, Grammas P, Nedergaard M, Nutt J, Pardridge W, Rosenberg GA, Smith Q, Drewes LR. Strategies to advance translational research into brain barriers. Lancet Neurol. 2008;7:84–96. [PubMed]
  • Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J Cell Biol. 2003;161:653–660. [PMC free article] [PubMed]
  • Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005a;2:3–14. [PMC free article] [PubMed]
  • Pardridge WM. Molecular biology of the blood-brain barrier. Mol Biotechnol. 2005b;30:57–70. [PubMed]
  • Pereanu W, Shy D, Hartenstein V. Morphogenesis and proliferation of the larval brain glia in Drosophila. Dev Biol. 2005;283:191–203. [PubMed]
  • Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature. 1985;316:817–819. [PubMed]
  • Sarkadi B, Homolya L, Szakacs G, Varadi A. Human multidrug resistance ABCB and ABCG transporters: participation in a chemoimmunity defense system. Physiol Rev. 2006;86:1179–1236. [PubMed]
  • Schinkel AH. The physiological function of drug-transporting P-glycoproteins. Semin Cancer Biol. 1997;8:161–170. [PubMed]
  • Schinkel AH. P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv Drug Deliv Rev. 1999;36:179–194. [PubMed]
  • Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A. 1997;94:4028–4033. [PMC free article] [PubMed]
  • Schwabe T, Bainton RJ, Fetter RD, Heberlein U, Gaul U. GPCR signaling is required for blood-brain barrier formation in drosophila. Cell. 2005;123:133–144. [PubMed]
  • Stork T, Engelen D, Krudewig A, Silies M, Bainton RJ, Klambt C. Organization and function of the blood-brain barrier in Drosophila. J Neurosci. 2008;28:587–597. [PubMed]
  • Strange K. Revisiting the Krogh Principle in the post-genome era: caenorhabditis elegans as a model system for integrative physiology research. J Exp Biol. 2007;210:1622–1631. [PubMed]
  • Sullivan W, Ashburner M, Hawley RS. Drosophila Protocols. Cold Spring harbor, NY: Cold Spring Harbor Laboratory Press; 2000.
  • Tepass U, Hartenstein V. The development of cellular junctions in the Drosophila embryo. Dev Biol. 1994;161:563–596. [PubMed]
  • Treherne JEPY. The insect blood- brain barrier. London: Academic; 1972.
  • van Den Elsen JM, Kuntz DA, Hoedemaeker FJ, Rose DR. Antibody C219 recognizes an alpha-helical epitope on P-glycoprotein. Proc Natl Acad Sci U S A. 1999;96:13679–13684. [PMC free article] [PubMed]
  • Wu CT, Budding M, Griffin MS, Croop JM. Isolation and characterization of Drosophila multidrug resistance gene homologs. Mol Cell Biol. 1991;11:3940–3948. [PMC free article] [PubMed]
  • Wu VM, Beitel GJ. A junctional problem of apical proportions: epithelial tube-size control by septate junctions in the Drosophila tracheal system. Curr Opin Cell Biol. 2004;16:493–499. [PubMed]
  • Yang J, McCart C, Woods DJ, Terhzaz S, Greenwood KG, ffrench-Constant RH, Dow JA. A Drosophila systems approach to xenobiotic metabolism. Physiol Genomics. 2007;30:223–231. [PubMed]
  • Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57:178–201. [PubMed]
PubReader format: click here to try

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links